about
Incretins and the intensivist: what are they and what does an intensivist need to know about them?Full predicted energy from nutrition and the effect on mortality and infectious complications in critically ill adults: a protocol for a systematic review and meta-analysis of parallel randomised controlled trialsStress hyperglycaemia in critically ill patients and the subsequent risk of diabetes: a systematic review and meta-analysisStress Induced Hyperglycemia and the Subsequent Risk of Type 2 Diabetes in Survivors of Critical IllnessModulation of individual components of gastric motor response to duodenal glucoseUnderstanding incretins.Gastric emptying and glycaemia in health and diabetes mellitus.Gastrointestinal dysfunction relating to the provision of nutrition in the critically ill.Dysglycemia and Glucose Control During Sepsis.Occult upper gastrointestinal mucosal abnormalities in critically ill patients.Liberal Glycemic Control in Critically Ill Patients With Type 2 Diabetes: An Exploratory Study.Critical Illness Is Associated With Impaired Gallbladder Emptying as Assessed by 3D Ultrasound.The rapid and accurate categorisation of critically ill patients (RACE) to identify outcomes of interest for longitudinal studies: a feasibility study.Energy-Dense Formulae May Slow Gastric Emptying in the Critically Ill.International observational study of nutritional support in mechanically ventilated patients following burn injury.Prevalence, risk factors, clinical consequences, and treatment of enteral feed intolerance during critical illness.Post-pyloric feeding tube placement in critically ill patients: Extending the scope of practice for Australian dietitians.Antecedent Hypoglycemia Does Not Attenuate the Acceleration of Gastric Emptying by Hypoglycemia.Postprandial hypotension in older survivors of critical illness.Targeted full energy and protein delivery in critically ill patients: a study protocol for a pilot randomised control trial (FEED Trial).Dysglycaemia in the critically ill and the interaction of chronic and acute glycaemia with mortality.Endogenous amylin and glucagon-like peptide-1 concentrations are not associated with gastric emptying in critical illness.Diabetes-Specific Formulae Versus Standard Formulae as Enteral Nutrition to Treat Hyperglycemia in Critically Ill Patients: Protocol for a Randomized Controlled Feasibility Trial.Pathophysiology and Treatment of Gastrointestinal Motility Disorders in the Acutely IllEnergy-Dense versus Routine Enteral Nutrition in the Critically IllOpinions and practices of blood glucose control in critically ill patients with pre-existing type 2 diabetes in Australian and New Zealand intensive care unitsIncident Diabetes in Survivors of Critical Illness and Mechanisms Underlying Persistent Glucose Intolerance: A Prospective Cohort StudySystematic review of incretin therapy during peri-operative and intensive careWhat Happens to Nutrition Intake in the Post-Intensive Care Unit Hospitalization Period? An Observational Cohort Study in Critically Ill AdultsNutrition Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double-Blind, Placebo-Controlled Trial of the Motilin Receptor Agonist Camicinal (GSK962040): The NUTRIATE StudyCharacteristics and Outcomes of Critically Ill Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Australia and New ZealandOutcome Measures in Critical Care Nutrition Interventional Trials: A Systematic ReviewSystematic Review With Meta-Analysis of Patient-Centered Outcomes, Comparing International Guideline-Recommended Enteral Protein Delivery With Usual Care20% Human Albumin Solution Fluid Bolus Administration Therapy in Patients After Cardiac Surgery (the HAS FLAIR Study)Translating the European Society for Clinical Nutrition and Metabolism 2019 guidelines into practiceHAS FLAIR Investigators Reply to Fluid Resuscitation After Cardiac Surgery: The Quest for the Ideal FluidGut dysmotility in the ICU: diagnosis and therapeutic optionsAn observational study investigating the use of patient-owned technology to quantify physical activity in survivors of critical illnessOutcomes Six Months after Delivering 100% or 70% of Enteral Calorie Requirements during Critical Illness (TARGET). A Randomized Controlled TrialHospital-acquired complications in intensive care unit patients with diabetes: A before-and-after study of a conventional versus liberal glucose control protocol
P50
Q26995464-7DFD7E02-C522-4221-9BAC-F1B79E12FF31Q28084764-4EE54577-C861-4010-83B5-88204C8ECC68Q34541305-8BF65ABA-399A-48DB-BFDE-F5935EBAD49CQ36185664-B620CACD-D1D2-4575-A9FA-B1E38A3514BCQ37221523-93ACA465-E96F-4533-A9F0-3120501FC384Q38241343-DE96226E-A9D6-4A76-962C-36362A663EA8Q38271037-873D3D13-736F-4068-92B5-C69C982964DBQ38324986-9CB2DBB6-2D57-4BCD-86AA-6B07995E4268Q38845330-CB20A7CC-E206-49A9-984C-468EA5217612Q39102984-B76D1FDD-1CB0-4191-8A1A-C14EB3DE59EAQ39675141-3FC71B19-8E89-4C2F-BEBF-FB41F8F9A21AQ39856851-6AA0CF64-59F3-4DD1-922D-8359F5698BA5Q40136599-9D84689E-B9BD-4342-B6BF-A64AF461E97DQ40874745-6BB1AF82-1E77-4AB5-A8CF-D0A20C618AB0Q43422537-8380A9FB-588F-4B9C-8FDF-37BFA2FEF59FQ44859515-1F69B503-8ED3-4985-B768-912F1C682789Q48091734-15445EBB-2982-4D91-B149-636154231BE5Q49651404-A06A9F1D-C881-4589-8275-B9774E9D128FQ50137539-8DBCD906-6507-41E6-A1BE-45C7DBBA7AF4Q50351488-8927FB4B-BEF0-487A-962E-74FD9BD88670Q51323673-C93EBA1A-D039-4B59-B1C4-8DA5966EA4E5Q51328766-ED3CE4A0-90FE-4695-8337-469F4992C69EQ52597972-8924D14F-5B88-45DD-B075-F0A971EF1F32Q57183055-91CC7DA5-902D-4FA0-8888-DD801E3FD444Q57804675-54E8C78D-C3EA-4907-8EF9-65DE4FD9377FQ57809227-E6AE9971-EFFF-486D-9054-08E3895C1E8BQ58609845-828760F2-01D0-4167-BC01-AF091A2D91E4Q59126600-6424C732-6F83-417C-80EB-1FC54559B62DQ89166007-46C1E6A2-6B7B-4F6B-BB1A-1AA1D91E55D3Q89348620-2064B581-A2DE-4B40-8E02-6CB5C0573296Q90065889-DE3331D7-CA5A-4B4C-A73C-8904F73E371DQ90102326-857FFC25-5E60-4C53-B5E7-9FE28BB446BDQ90738438-716C1CAC-07D5-40D4-A054-C7D747FF2265Q92087931-29C9E285-2FB0-4150-B39B-5208940C7E0BQ92153436-415BC4E3-3AA2-4242-94C1-9A92A262D953Q92263364-0A3DA773-1B4A-4394-9035-9CD3B9D48A9CQ92264337-BF937338-50BB-495A-BA34-62B9223BA487Q92419922-EAC6B270-DBCA-4ABE-B1DC-2C556D931922Q92436878-F7BC6E1F-40D7-41DB-A430-D1646B36C9F4Q92438838-3BADB546-2955-43A5-8172-F201E40D4BC1
P50
description
researcher
@en
wetenschapper
@nl
name
Adam M Deane
@en
Adam M Deane
@nl
type
label
Adam M Deane
@en
Adam M Deane
@nl
prefLabel
Adam M Deane
@en
Adam M Deane
@nl
P31
P496
0000-0002-7620-5577